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DAS28Abstract Aim of the work: To evaluate the frequency of anti-mutated citrullinated vimentin
antibodies (MCV) in rheumatoid arthritis (RA) patients and to correlate it with disease activity
and various disease manifestations.
Patients and methods: Fifty RA patients were recruited from the rheumatology and rehabilita-
tion outpatient clinic, Kasr Al-Aini. Thirty healthy subjects served as controls. All patients were
subjected to full history taking and clinical examination including general and joint assessment.
Disease activity was assessed by the disease activity score (DAS-28) and functional ability was
evaluated by the Modiﬁed Health Assessment Questionnaire (MHAQ). Anti-MCV and anti-cyclic
citrullinated peptide (anti-CCP) were assayed by ELISA in patients and controls. Plain X-ray was
performed on the hands and wrists and Sharp score was used to assess the erosions and joint space
narrowing.
Results: A highly signiﬁcant elevation of serum anti-MCV in RA patients (135.82 ± 126.81
U/ml) compared to controls (13.63 ± 8.48 U/ml) (p< 0.0001) was found. Anti-MCV showed a
sensitivity of 84% and speciﬁcity of 80%. There was a signiﬁcant difference between anti-MCV
positive and anti-MCV negative patients as regards MHAQ (1.07 ± 0.74 vs. 0.52 ± 0.37,
p= 0.005) and Sharp erosion score (12.93 ± 23.55 vs. 4 ± 2.2, p= 0.02). Anti-CCP showed a
66 R.I. El Shazly et al.sensitivity of 70% and speciﬁcity of 100%. There was a signiﬁcant difference between the
speciﬁcities of both markers (p= 0.03). There was no signiﬁcant correlation of the anti-MCV with
the clinical manifestations, MHAQ, DAS28 or Sharp score. Anti-MCV signiﬁcantly correlated with
anti-CCP (p< 0.0001).
Conclusion: Anti-MCV test has a signiﬁcant association with the functional disability and radio-
logic progression in RA and could be considered as a promising biomarker.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Rheumatoid arthritis (RA) is a common systemic autoimmune
disease. Its prevalence is between 0.5% and 1% worldwide. It
is mainly characterised by persistent joint inﬂammation that
results in loss of joint function andmorbidity [1]. The American
College of Rheumatology (ACR) 1987 revised criteria could still
be used in the classiﬁcation of RA and is primarily based on
clinical parameters. The only serological criteria being IgM
rheumatoid factor (IgM RF). However, the criteria may be
insufﬁcient for the diagnosis of earlyRA, as they are based upon
measurements of disease classiﬁcation predominately featuring
manifestations typical of later-stage disease [2].
Numerous serological markers of RA have been described
over the past 50 years. Among all these, Anti-Cyclic Citrulli-
nated Peptide (CCP) antibodies have been proven to be highly
speciﬁc, diagnostic and prognostic markers in RA [3]. In July
2010, the 2010 ACR/European League against Rheumatism
(EULAR) rheumatoid arthritis classiﬁcation criteria was intro-
duced. These new classiﬁcation criteria included anti-CCP test-
ing [4], overruled the ‘‘old’’ ACR criteria 1987 [5] and are
adapted for early RA diagnosis. The newest member of this
autoantibody family is anti-mutated citrullinated vimentin
(MCV) [3].
Vimentin is a protein found in mesenchymal and endothe-
lial cells, monocytes and activated macrophages, citrullinated
by peptidyl arginine deaminase enzyme [6]. In RA this
ccitrullinated peptide activates T-lymphocytes by binding on
HLA-DR4 on the surface of antigen presenting cells and
may contribute to certain pathways in the pathogenesis of
RA [7]. Studies on the diagnostic accuracy of anti-CCP anti-
bodies report a higher sensitivity (up to 78%) and speciﬁcity
(up to 95%) of anti-MCV. Besides the higher sensitivity it
has been shown that anti-MCV is an even better prognostic
marker for the outcome of RA, it correlates well with the dis-
ease activity score [7].
The aim of this work is to evaluate the frequency of anti-
MCV antibodies in RA patients and to correlate its relation
to disease activity and manifestations.2. Patients and methods
Fifty RA patients attending the Kasr Al Aini Rheumatology
and Rehabilitation Outpatient Clinic, and 30 healthy controls
were involved in this study. All patients were previously diag-
nosed according to the 2010 ACR/EULAR RA classiﬁcation
criteria [4].
All patients gave informed consent to participate in the
study, which was approved by the Kasr Al Aini medical ethics
committee. Patients were subjected to detailed history, generaland musculoskeletal examination and measurement of the
28-joint count of tender and swollen joint with calculation of
the disease activity score (DAS-28) for each RA patient by
DAS-28 score calculator [8].
Modiﬁed Health Assessment Questionnaire (MHAQ) was
used for assessing the functional ability of the patients [9,10].
2.1. Laboratory tests
All patients were subjected to routine laboratory
investigations.
Rheumatoid factor was assayed with a quantitative immu-
no-nephelometry test (Behring, Marburg, Germany).
Anti-CCP was measured using the Immunoscan CCPlus
test kit using enzyme-linked immunosorbent assay (ELISA)
for qualitative and semiquantitative detection of IgG antibod-
ies to Cyclic Citrullinated Peptides (CCP) in human sera.
Normal reference level is up to 25 U/ml.
Anti-MCV was measured using an indirect solid phase ELI-
SA for the quantitative measurement of IgG class autoanti-
bodies against Mutated Citrullinated Vimentin (MCV) in
human serum (using kit from ORGENTEC Diagnostika
GmbH). Normal reference level is up to 20 U/ml.
2.2. Conventional radiography
Sharp score was calculated to evaluate radiographic changes in
RA patients and included the Sharp erosion score and the joint
space narrowing (JSN) score [11].
Statistical methods: Comparison was done using Student’s t
test for independent samples comparing 2 groups and the
Mann Whitney U test. Comparison of numerical variables be-
tween more than two groups was done using the Kruskal
Wallis test. For comparing categorical data, Chi square (v2)
test was performed. Correlation between various variables
was done using Spearman rank correlation equation for non-
normal variables. A linear multiple regression analysis for
anti-MCV levels (dependent variable) was performed to assess
the effect of possible independent variables. p-values less than
0.05 were considered statistically signiﬁcant. All statistical cal-
culations were done using computer programs SPSS version 15
for Microsoft Windows.
3. Results
The study included ﬁfty RA patients, 47 females (94%) and 3
males (6%). The demographic, clinical and laboratory charac-
teristics of the RA patients are demonstrated in Tables 1 and 2.
Serum Anti-MCV levels in the patients were detected with a
mean of 135.82 ± 126.81 U/ml. These values were signiﬁcantly
Table 1 Demographic and clinical features of the rheumatoid arthritis (RA) patients (N= 50).
Feature Rheumatoid arthritis patients (n= 50)
Range Mean ± SD
Age (years) 23–65 45.1 ± 10.71
Age at disease onset (years) 12–59 36.7 ± 10.19
Disease duration (years) 1–28 8.33 ± 7.22
DAS 28 2.21–8.2 5.17 ± 1.49
MHAQ 0–2.75 1.03 ± 0.75
Sharp score (erosions) 0–111 11.5 ± 21.8
Sharp score (JSN) 44–108 66.3 ± 16.3
Number Percent
Subcutaneous nodules 13 26
Sjo¨gren’s syndrome 7 14
Pulmonary manifestations 7 14
Cardiac manifestations 0 0
GIT manifestations 3 6
Neurological manifestations 3 6
DAS: Disease Activity Score; MHAQ: Modiﬁed Health Assessment Questionnaire; JSN: Joint space narrowing.
Table 2 The laboratory features of the rheumatoid arthritis (RA) patients (N= 50).
Laboratory investigation Rheumatoid arthritis patients (n= 50)
Range Mean ± S.D
ESR (mm/1st hour) 8–135 53.92 ± 29.73
Hb (gm/dl) 9.6–14.6 11.73 ± 1.09
TLC (·103/mm3) 2.4–19.6 8.079 ± 2.89
Platelets (·103/mm3) 153–755 333.9 ± 115.6
AST (U/L) 4–77 20.88 ± 14.65
ALT (U/L) 5–85 20.34 ± 17.53
Creatinine (mg/dl) 0.4–1.15 0.74 ± 0.21
Number Percent
Anti-CCP positivity 35 70
RF positivity 38 76
ESR: Erythrocytes Sedimentation Rate; Hb: Haemoglobin; TLC: Total Leucocytic Count; AST: Aspartate Transferase; ALT: Alanine
Transaminase; RF: rheumatoid factor; anti-CCP: Anti-Cyclic Citrullinated Peptide.
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which had a mean of 13.63 ± 8.48 U/ml (p< 0.0001)
(Fig. 1). The mean level of MCV in the 3 male patients was
higher (165.3 ± 165.97 U/ml) compared to the level in females
(133.94 ± 125.98 U/ml).
Methotrexate was received by 42 patients (84%) with a
dose ranging from 12.5 to 25 mg/week (17 ± 7.94 mg/week).
Eighteen patients (36%) received Hydroxychloroquine and
corticosteroids (prednisone) were received by 22 (44%) with
a dose ranging from 2.5 to 10 mg/day (3.25 ± 3.75 mg/d).
Leﬂunomide (20 mg/day) was received by 12 patients (24%).
Non steroidal anti-inﬂammatory drugs (NSAIDs) were taken
regularly by 7 patients (14%) and at need by 36 (72%).
The sensitivity of anti-MCV was 84% with 80% speciﬁcity.
The serum anti-CCP levels were detected with a mean of
252.63 ± 284.51. These values were signiﬁcantly higher than
the corresponding values of the control groupwhich had amean
of 1.72 ± 1.104 (p< 0.0001). The sensitivity of anti-CCP was
70% with 100% speciﬁcity. There was no signiﬁcant difference
between the sensitivities of both anti-MVC and anti-CCP(p= 0.602), however, there was a statistically high signiﬁcance
between the speciﬁcities of both markers (p= 0.0314).
The patients were divided into 2 groups; anti-MCV positive
and anti-MCV negative. Both groups were compared as regards
various disease parameters (Table 3). There was no signiﬁcant
difference between anti-MCV positive and negative patients as
regards the age, age of onset and disease duration. Anti-MCV
positive patients had higher ESR and DAS28 scores, however,
they were statistically insigniﬁcant (p= 0.27 and 0.17, respec-
tively). TheMHAQscore, Sharp erosion score, and anti-CCP ti-
tres were signiﬁcantly higher in the RA patients with a positive
anti-MCV compared to those with a negative anti-MCV
(p= 0.005, p= 0.02, and p= 0.01, respectively) (Fig. 2). There
was no signiﬁcant difference between anti-MCV positive and
negative patients as regards to ESR and DAS28.
There was no signiﬁcant difference between anti-MCV
and anti-CCP regarding the demographic, clinical or lab-
oratory features of the RA patients. The rheumatoid fac-
tor (RF) positivity was more frequent in those with a
positive anti-CCP (31/35 patients = 88.57%) compared
Figure 1 Anti-mutated citrullinated vimentin (MCV) antibodies’
level in rheumatoid arthritis patients and controls.
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80.95%).
No signiﬁcant correlation could be elicited between serum
anti-MCV and DAS28, MHAQ, ESR, Sharp score and fre-
quency of extra-articular manifestations. The relation was neg-
ative with the age, age at disease onset, disease duration,
presence of Sjo¨gren syndrome and pulmonary manifestations,
yet insigniﬁcant. Only the correlation of the anti-MCV with
the anti-CCP antibodies was highly signiﬁcant (r= 0.49,
p< 0.0001) (Fig. 3). Furthermore, on performing a regression
analysis, on the predictors of an increased anti-MCV level,
only the anti-CCP was signiﬁcant (B= 0.18, p = 0.006)Table 3 Comparison between anti-MCV positive and negative
demographic, clinical, laboratory and radiological characteristics.
Characteristic mean ± SD Anti-MC
Positive
Anti-MCV (U/ml) 160.28 ±
Age (years) 45.21 ±
Onset (years) 36.02 ±
Duration (years) 9.14 ±
ESR (mm/1st hour) 56.05 ±
DAS28 5.29 ±
MHAQ 1.07 ±
Anti-CCP (U/ml) 291.56 ±
Sharp Score Erosion 12.93 ±
JSN 68 ±
ESR: Erythrocyte Sedimentation Rate; MCV: Mutated Citrullinated Vim
Disease Activity Score 28; Anti-CCP: Anti-Cyclic Citrullinated Peptide;among other independent factors including the age, disease
duration, ESR, DAS28, erosion score and methotrexate dose.4. Discussion
The Rheumatoid arthritis disease course can follow two dis-
tinct clinical phenotypes characterised by mild disease activity
with less joint destruction and fewer co-morbidities or high dis-
ease activity, more joint destruction and higher co-morbidities.
Therefore, it is important to select patients who would beneﬁt
most from aggressive treatment in the early phase of the
disease [12].
Anti-citrullinated protein antibodies (ACPA) have been re-
ported as more speciﬁc serological markers of RA. They pro-
vide a superior alternative to the RF test in laboratory
diagnostics of RA This autoantibody family is an overlapping
group of antibodies dependent on the citrullination of arginine
residue [13]. Only Anti-Cyclic Citrullinated Peptide (CCP)
antibody is used in clinical practice. Due to the high clinical
potential of ACPAs, this biomarker was deservedly included
in the new RA classiﬁcation criteria released based on collab-
orative efforts between the ACR and EULAR [4]. A new mem-
ber of this autoantibody family is anti-MCV [3]. With this as a
background, we were stimulated to study the role of anti-MCV
as a marker in RA and compare it to anti-CCP.
In the present study, we found that the sensitivity of anti-
MCV is 84% and the speciﬁcity is 80%. This agrees with the
studies of Poulsom and Charles [2] and Bang et al. [14] who re-
ported a sensitivity of 84% and 82% and speciﬁcity of 87%
and 88%, respectively. However Liu et al. [3] reported a lower
sensitivity and higher speciﬁcity (78.2% and 93.4%, respec-
tively). Sizova [15] reported a lower sensitivity (53.3%) and
comparable speciﬁcity (83.3%).
In this study there was no signiﬁcant difference between RA
patients and healthy controls from one side and between
patients who were anti-MCV positive and those who were
anti-MCV negative with respect to age, age of onset, disease
duration, sex and extra-articular manifestations. This was in
agreement with the results found in the studies of Wagner
et al. [7] and Engelmann et al. [16].rheumatoid arthritis (RA) patients as regards some of the
V p-Value
(N= 42) Negative (N= 8)
124.02 7.39 ± 6.32 <0.0001
10.79 44.50 ± 11.14 0.8 (NS)
10.13 40.25 ± 10.47 0.33 (NS)
7.54 4.03 ± 2.73 0.06 (NS)
30.63 42.75 ± 22.8 0.28 (NS)
1.516 4.58 ± 1.24 0.18 (NS)
0.74 0.52 ± 0.37 0.005 (S)
287.13 71.1 ± 171.7 0.01 (S)
23.55 4 ± 2.2 0.02 (S)
16.63 57.5 ± 11.92 0.053 (NS)
entin; MHAQ: Modiﬁed Health Assessment Questionnaire; DAS28:
JSN: Joint space narrowing; NS: Non signiﬁcant; S: Signiﬁcant.
Figure 2 Comparison of the Modiﬁed Health Assessment Questionnaire (MHAQ), Sharp score for erosions and anti-cyclic citrullinated
peptide (CCP) antibodies’ level in rheumatoid arthritis patients with positive and negative anti-mutated citrullinated vimentin (MCV)
antibodies. * = Signiﬁcantly different from the corresponding value in those with a negative anti-MCV.
Figure 3 Correlation of the anti-mutated citrullinated vimentin
(MCV) antibodies and anti-cyclic citrullinated peptide (CCP)
antibodies in rheumatoid arthritis patients.
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positive and anti-MCV normal groups as regards parameters
of disease activity represented in the Disease Activity Score
28 (DAS28) and ESR, although anti-MCV positive patients
had higher ESR and DAS28 scores than the anti-MCV neg-
ative group. Furthermore, no signiﬁcant correlation was pres-
ent between anti-MCV level and these parameters. This
ﬁnding was in agreement with the ﬁndings of other studies
[3,16,17] who showed that the DAS28 was higher in the
anti-MCV-positive group than in the negative group, how-
ever no signiﬁcant statistical correlation was found between
circulating levels of anti-MCV with DAS28 and ESR. They
all concluded that it is not useful to monitor disease activity
with anti-MCV levels.
The present study did not ﬁnd any correlation between anti-
MCV and MHAQ, however, there was a statistically signiﬁ-
cant difference between anti-MCV positive and negative
groups as regards MHAQ. This ﬁnding suggests that anti-
MCV could be useful for the assessment of functional disabil-
ity in RA.A signiﬁcant difference between anti-MCV positive and
negative groups as regarding the radiographic damage of joints
was present with a higher mean Sharp score in the positive
group. This ﬁnding points to the important role anti-MCV
positivity in disease severity as assessed by the radiological
damage of joints. This was in agreement with the results of
other studies [3,17,18] that proved aggressive peripheral joint
disease in anti-MCV positive groups. In addition, Liu et al.
[3] remarkably proved that anti-MCV-positive patients with
early RA already had more severe radiographic damage than
those with a negative anti-MCV. However, other coworkers
[7,19,20] did not ﬁnd a signiﬁcant correlation between anti-
MCV level and radiographic scores.
In the current work, anti-MCV was strongly correlated
with anti-CCP but weakly correlated with RF. This ﬁnding
is consistent with the literature in the studies done by Mutlu
et al. [21] and Mathsson et al. [19]. In the present study, the
anti-CCP was positive in 35/50 (70%) of the RA patients while
none of the controls had a positive anti-CCP.
In our study, the reported sensitivity for anti-CCP was 70%
and speciﬁcity was 100%. The anti-MCV sensitivity for RA
was found to be higher than that of the anti-CCP (84% vs.
70%). Comparable results have been found in the studies of
Wagner et al. [6] (71.5 vs. 69%), Bang et al. [14] (sensitivity
82 vs. 72%), Coenen et al. [22] (74.5 vs. 66.4%), Soo´s et al.
[23] (75.6 vs. 66.4%) and Mathsson et al. [24] (70.7 vs.
57.9%). This concludes that the sensitivity of anti-MCV is
superior to anti-CCP.
As for the speciﬁcity, anti-CCP was reported to be higher
when compared to anti-MCV in our study (100 vs. 80%
respectively). This was in agreement with the results of Wagner
et al. [7] (97.6 vs. 81.3%), Dejaco et al. [24] (98.7 vs. 90.8%),
Coenen et al. [22] (96% vs. 90.3%) and Soos et al. [23]
(98.3% vs. 91.5%). Only one study done by Bang et al. [14]
found a higher speciﬁcity of anti-MCV compared to the anti-
CCP (98% vs. 96%).
In conclusion, despite the great expectations, the anti-MCV
assay did not provide signiﬁcant additional diagnostic value
over the anti-CCP assay. Although credited with higher sensi-
tivity, the anti-MCV assay obtained lower speciﬁcity in com-
parison to the anti-CCP assay which is clinically the most
70 R.I. El Shazly et al.relevant. However, it could be of diagnostic importance in
anti-CCP negative patients due to its high sensitivity. Further
studies on a larger number of cases and with a longitudinal
study design are required to prove the relation of anti-MCV
with disease activity and different manifestations. For now,
it seems that the only obvious advantage of anti-MCV over
anti-CCP antibodies is a closer association with radiologic pro-
gression, thus making the anti-MCV titre useful in detecting a
more aggressive and erosive disease. Testing for these antibod-
ies early in the disease can guide the choice of initial therapy,
reserving aggressive regimens for those with positive anti-
MCV titres and high radiographic scores who are suspected
to have an aggressive early erosive disease course.
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